DR. RICHARD VAL HYMAS M.D.
Prescription History 1700149713
Radiology - Radiation Oncology in Royal Oak, MI


Quality Rating: 83.32 out of 100 score

NPI Status: Active since June 25, 2012

Contact Information

3601 W 13 MILE RD
ROYAL OAK, MI
ZIP 48073
Phone: (248) 551-0570

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. RICHARD VAL HYMAS M.D., an active Radiation Oncology specialist practicing in Royal Oak, MI. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 320 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 121 claims alone.


Anastrozole

Generic Formulation: AnastrozoleSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 121
30-Day Fills 330.1
Days Supply 9,819
MI State Average Benchmarks
Peer Average Claims73.0
Peer Average 30-Day Fills178.7
Peer Average Days Supply5,341
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 65.8% higher than the standard regional baseline profile for MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,949.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.37

State Avg Cost Per Claim

$34.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Bicalutamide

Generic Formulation: BicalutamideSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 30
30-Day Fills 38.5
Days Supply 1,122
MI State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills58.2
Peer Average Days Supply1,724
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $771.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.73

State Avg Cost Per Claim

$47.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Bicalutamide is used to treat prostate cancer. This medication works by blocking the action of male hormones in the prostate, slowing the growth of cancer cells. This medication should not be used in women and children.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 146
MI State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills34.9
Peer Average Days Supply484
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.1% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $123.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.21

State Avg Cost Per Claim

$15.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Hydrocodone-Acetaminophen

Generic Formulation: Hydrocodone/AcetaminophenSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 169
MI State Average Benchmarks
Peer Average Claims94.0
Peer Average 30-Day Fills95.2
Peer Average Days Supply2,065
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.7% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $373.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.78

State Avg Cost Per Claim

$19.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to relieve moderate to severe pain. It contains an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen). Hydrocodone works in the brain to change how your body feels and responds to pain. Acetaminophen can also reduce a fever.

Letrozole

Generic Formulation: LetrozoleSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 33.3
Days Supply 1,000
MI State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills116.3
Peer Average Days Supply3,475
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 78.0% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $206.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.79

State Avg Cost Per Claim

$40.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 35
30-Day Fills 82.0
Days Supply 2,460
MI State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills86.8
Peer Average Days Supply2,593
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,139.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.57

State Avg Cost Per Claim

$42.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Tamsulosin Hcl

Generic Formulation: Tamsulosin HclSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 60
30-Day Fills 162.0
Days Supply 4,845
MI State Average Benchmarks
Peer Average Claims80.0
Peer Average 30-Day Fills181.6
Peer Average Days Supply5,395
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,879.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.33

State Avg Cost Per Claim

$21.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tamsulosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tamsulosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Venlafaxine Hcl Er

Generic Formulation: Venlafaxine HclSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 27
30-Day Fills 76.5
Days Supply 2,295
MI State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills64.8
Peer Average Days Supply1,920
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $739.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$27.40

State Avg Cost Per Claim

$33.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Venlafaxine is used to treat depression, anxiety, panic attacks, and social anxiety disorder (social phobia). It may improve your mood and energy level and may help restore your interest in daily living. It may also decrease fear, anxiety, unwanted thoughts, and the number of panic attacks. Venlafaxine is known as a serotonin-norepinephrine reuptake inhibitor (SNRI). It works by helping to restore the balance of certain natural substances (serotonin and norepinephrine) in the brain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. RICHARD VAL HYMAS M.D. provides transparency into local medical care patterns within Royal Oak, MI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Radiation Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.